Literature DB >> 33321734

Neurosteroids and Focal Epileptic Disorders.

Maxime Lévesque1, Giuseppe Biagini2, Massimo Avoli1,3.   

Abstract

Neurosteroids are a family of compounds that are synthesized in principal excitatory neurons and glial cells, and derive from the transformation of cholesterol into pregnenolone. The most studied neurosteroids-allopregnanolone and allotetrahydrodeoxycorticosterone (THDOC)-are known to modulate GABAA receptor-mediated transmission, thus playing a role in controlling neuronal network excitability. Given the role of GABAA signaling in epileptic disorders, neurosteroids have profound effects on seizure generation and play a role in the development of chronic epileptic conditions (i.e., epileptogenesis). We review here studies showing the effects induced by neurosteroids on epileptiform synchronization in in vitro brain slices, on epileptic activity in in vivo models, i.e., in animals that were made epileptic with chemoconvulsant treatment, and in epileptic patients. These studies reveal that neurosteroids can modulate ictogenesis and the occurrence of pathological network activity such as interictal spikes and high-frequency oscillations (80-500 Hz). Moreover, they can delay the onset of spontaneous seizures in animal models of mesial temporal lobe epilepsy. Overall, this evidence suggests that neurosteroids represent a new target for the treatment of focal epileptic disorders.

Entities:  

Keywords:  GABA; allopregnanolone; allotetrahydrodeoxycorticosterone; epilepsy; epileptogenesis; ictogenesis; neurosteroids

Year:  2020        PMID: 33321734      PMCID: PMC7763947          DOI: 10.3390/ijms21249391

Source DB:  PubMed          Journal:  Int J Mol Sci        ISSN: 1422-0067            Impact factor:   5.923


  99 in total

1.  Synchronous GABA-mediated potentials and epileptiform discharges in the rat limbic system in vitro.

Authors:  M Avoli; M Barbarosie; A Lücke; T Nagao; V Lopantsev; R Köhling
Journal:  J Neurosci       Date:  1996-06-15       Impact factor: 6.167

2.  The anti-ictogenic effects of levetiracetam are mirrored by interictal spiking and high-frequency oscillation changes in a model of temporal lobe epilepsy.

Authors:  Maxime Lévesque; Charles Behr; Massimo Avoli
Journal:  Seizure       Date:  2014-11-26       Impact factor: 3.184

3.  Anticonvulsive properties of pregnanolone emulsion compared with althesin and thiopentone in mice.

Authors:  S Høgskilde; J Wagner; P Carl; N Anker; H R Angelo; M B Sørensen
Journal:  Br J Anaesth       Date:  1988-10       Impact factor: 9.166

4.  Sulfated and unsulfated steroids modulate gamma-aminobutyric acidA receptor function through distinct sites.

Authors:  M Park-Chung; A Malayev; R H Purdy; T T Gibbs; D H Farb
Journal:  Brain Res       Date:  1999-05-29       Impact factor: 3.252

5.  Characterization of brain neurons that express enzymes mediating neurosteroid biosynthesis.

Authors:  Roberto C Agís-Balboa; Graziano Pinna; Adrian Zhubi; Ekrem Maloku; Marin Veldic; Erminio Costa; Alessandro Guidotti
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-19       Impact factor: 11.205

6.  Messenger RNAs encoding steroidogenic enzymes are expressed in rodent brain.

Authors:  M Strömstedt; M R Waterman
Journal:  Brain Res Mol Brain Res       Date:  1995-12-01

7.  Randomized, double-blind, placebo-controlled phase 2 study of ganaxolone as add-on therapy in adults with uncontrolled partial-onset seizures.

Authors:  Michael R Sperling; Pavel Klein; Julia Tsai
Journal:  Epilepsia       Date:  2017-02-23       Impact factor: 5.864

8.  Neurosteroids in the mouse brain: behavioral and pharmacological effects of a 3 beta-hydroxysteroid dehydrogenase inhibitor.

Authors:  J Young; C Corpéchot; F Perché; B Eychenne; M Haug; E E Baulieu; P Robel
Journal:  Steroids       Date:  1996-03       Impact factor: 2.668

9.  Role of anticonvulsant and antiepileptogenic neurosteroids in the pathophysiology and treatment of epilepsy.

Authors:  Doodipala Samba Reddy
Journal:  Front Endocrinol (Lausanne)       Date:  2011-10-05       Impact factor: 5.555

10.  Brexanolone as adjunctive therapy in super-refractory status epilepticus.

Authors:  Eric S Rosenthal; Jan Claassen; Mark S Wainwright; Aatif M Husain; Henrikas Vaitkevicius; Shane Raines; Ethan Hoffmann; Helen Colquhoun; James J Doherty; Stephen J Kanes
Journal:  Ann Neurol       Date:  2017-09-11       Impact factor: 10.422

View more
  6 in total

Review 1.  Pathophysiological Heterogeneity of the BBSOA Neurodevelopmental Syndrome.

Authors:  Michele Bertacchi; Chiara Tocco; Christian P Schaaf; Michèle Studer
Journal:  Cells       Date:  2022-04-08       Impact factor: 7.666

Review 2.  Experimental GABA A Receptor Agonists and Allosteric Modulators for the Treatment of Focal Epilepsy.

Authors:  Slobodan M Janković; Miralem Dješević; Snežana V Janković
Journal:  J Exp Pharmacol       Date:  2021-03-08

3.  Perisomatic Inhibition and Its Relation to Epilepsy and to Synchrony Generation in the Human Neocortex.

Authors:  Estilla Zsófia Tóth; Felicia Gyöngyvér Szabó; Ágnes Kandrács; Noémi Orsolya Molnár; Gábor Nagy; Attila G Bagó; Loránd Erőss; Dániel Fabó; Boglárka Hajnal; Bence Rácz; Lucia Wittner; István Ulbert; Kinga Tóth
Journal:  Int J Mol Sci       Date:  2021-12-24       Impact factor: 5.923

Review 4.  Allopregnanolone: An overview on its synthesis and effects.

Authors:  Silvia Diviccaro; Lucia Cioffi; Eva Falvo; Silvia Giatti; Roberto Cosimo Melcangi
Journal:  J Neuroendocrinol       Date:  2021-06-29       Impact factor: 3.870

5.  The Neuroactive Steroid Pregnanolone Glutamate: Anticonvulsant Effect, Metabolites and Its Effect on Neurosteroid Levels in Developing Rat Brains.

Authors:  Eva Kudova; Pavel Mares; Martin Hill; Katerina Vondrakova; Grygoriy Tsenov; Hana Chodounska; Hana Kubova; Karel Vales
Journal:  Pharmaceuticals (Basel)       Date:  2021-12-30

Review 6.  [Pharmacotherapy and intensive care aspects of status epilepticus: update 2020/2021].

Authors:  Gabrielė Saitov; Annekatrin Müller; Börge Bastian; Dominik Michalski
Journal:  Anaesthesist       Date:  2021-07-01       Impact factor: 1.041

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.